Im­bria touts PhII suc­cess in hy­per­trophic car­diomy­opa­thy, adding fu­el to over­all ef­fi­ca­cy pro­file

Im­bria Phar­ma­ceu­ti­cals’ par­tial fat­ty acid ox­i­da­tion in­hibitor im­proved out­comes in Phase II non-ob­struc­tive hy­per­trophic car­diomy­opa­thy pa­tients, with the com­pa­ny not­ing that the as­set’s ef­fi­ca­cy could …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER